Merger of Lachema and Pliva Krakow approved
The Czech anti-monopoly office (UOHS) has approved a merger betweendrugs producer Lachema and its Pliva Krakow counterpart from Poland, according to the CTK news agency's Business News. The approval was given because the two companies have not competed with each other in the Czech market.
In addition, the UOHS believes that the merger will increase Lachema's competitiveness because it will be given access to Pliva's research facilities and marketing network. Pliva purchased a 66.66% stake in Lachema last year for $26.5 million (Marketletter November 29, 1999).
Lachema recorded a gross profit of 25 million koruna ($651,600) on sales worth 924 million koruna in the first nine months of 1999.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze